OXFORD, United Kingdom and MARLBOROUGH, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2018 financial results prior to market open on Tuesday, May 1 , 2018. Dr.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, is scheduled to present at the following upcoming
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the appointment of Mark Klausner to the Company's Board of Directors. Mr.
2017 marks the 13 th consecutive year of at least 20% year-over-year constant currency revenue growth >25% pro forma organic growth for the year in tick-borne disease and other revenue Balance sheet strengthened by December patent infringement settlement, which included a cash receipt of $27.5
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2017 financial results prior to market open on Tuesday,
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that based on preliminary unaudited financial data, the Company expects revenue for the fourth quarter of 2017 will
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 36th Annual J.P.
Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
Harnessing the power of T cell measurement
